Drawing for GALVUS MET

USPTO serial 88676987

GALVUS MET

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
FITZSIMONS, MICHAEL R
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GALVUS MET?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 12, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 12, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 18, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 17, 2022EX5GSOU EXTENSION 5 GRANTED—
Nov 16, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 7, 2022EXT5SOU EXTENSION 5 FILED—
Nov 7, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 12, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 10, 2022EX4GSOU EXTENSION 4 GRANTED—
May 10, 2022EXT4SOU EXTENSION 4 FILED—
May 10, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 11, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 9, 2021EX3GSOU EXTENSION 3 GRANTED—
Nov 9, 2021EXT3SOU EXTENSION 3 FILED—
Nov 9, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 11, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 9, 2021EX2GSOU EXTENSION 2 GRANTED—
May 9, 2021EXT2SOU EXTENSION 2 FILED—
May 9, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 13, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 11, 2020EX1GSOU EXTENSION 1 GRANTED—
Nov 11, 2020EXT1SOU EXTENSION 1 FILED—
Nov 11, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 12, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 17, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 17, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 26, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 7, 2020ALIEASSIGNED TO LIE—
Jan 29, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 28, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 27, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 27, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 15, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 15, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 15, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2020DOCKASSIGNED TO EXAMINER—
Nov 5, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 5, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance